Background {#Sec1}
==========

The prevalence of dementia is increasing, and it is anticipated that by the year 2050, there will be more than 131.5 million living with the diagnosis worldwide \[[@CR1]\]. Primary progressive aphasia (PPA) describes a group of language-led dementias, often associated with frontotemporal dementia and considered the leading cause of dementia in people of working age \[[@CR2], [@CR3]\]. PPA initially presents solely as a language difficulty with impairments that superficially resemble classical stroke aphasia syndromes but worsening over time. There are three major PPA syndromes, namely semantic variant that affects the use and understanding of word meanings, logopenic variant that results in difficulties in word retrieval, and non-fluent agrammatic variant where individuals may present with either or both verbal dyspraxia and grammatical errors \[[@CR3]\]. In many cases, other cognitive deficits (e.g. with memory) may not present for several years. As a result, people with PPA are often highly motivated to seek speech and language therapy. Perhaps, as a result of this retained awareness, people with PPA are prone to low self-esteem and poor confidence \[[@CR4]\].

The research evidence for speech and language therapy interventions for PPA is sparse and is predominantly limited to naming therapies, word finding difficulty being a common impairment \[[@CR5]--[@CR11]\]. However, naming is often not the main limitation on communication function in PPA, and interventions are required to address real world communication function. This is particularly relevant given that prognosis in PPA is for loss of function, rather than improvement as in stroke aphasia, and there is a need to engage family/carers in speech and language therapy. Yet, there is a paucity of literature examining the impact that speech and language therapists (SLTs) can have in supporting a person with PPA and their family/carers with conversation \[[@CR12], [@CR13]\]. Nevertheless, SLTs in clinical practice report using communication training programs more often than naming therapies \[[@CR14]\]. This is not surprising when reports suggest many patients disengage from naming therapies due to the frustration of practising individual words they will inevitably lose as the disease progresses \[[@CR2]\].

SLTs have been reported to prioritise working on communication between people with PPA and their conversation partners (CPs), specifically targeting the use of meaningful strategies for both the person and their family members \[[@CR15]\] using a variety of communication training approaches from the stroke and brain injury literature that have not been trialled for PPA \[[@CR16]\]. Communication skills training has a growing evidence base in these fields \[[@CR17], [@CR18]\]. Programs have in common individualised feedback (often video-based) on facilitators (behaviours that help conversation such as using multi-modal communication---speaking, gesture, drawing and other communication aids) and barriers (behaviours that create problems in conversation such as the use of 'test' questions, asked by the CP despite already knowing the answer) to communication, followed by strategy training, with the aim of maximising the success of everyday conversations \[[@CR19]\]. Whilst many such programs focus on training the CP only, Better Conversations with Aphasia (BCA) \[[@CR20]\] aims to change the conversation skills of both a person with post-stroke aphasia and a CP \[[@CR21]--[@CR23]\]. BCA is a free online package consisting of a therapy manual and training materials for SLTs. Since its launch in 2013, it has attracted over 5000 users worldwide. BCA utilises video feedback to enable participants to reflect on communication facilitators and barriers, and the authors believe this to be a key mediator for improved conversation skill. In a UK-wide survey, a high proportion of SLTs report working with both the person with PPA and their CP and using BCA as a tool to support this therapy above other tools that only target the CP \[[@CR16]\], thus motivating BCA as a target for adaptation to PPA over other possible alternative stroke aphasia programs.

In summary, the evidence base for communication training in PPA is limited, yet front-line SLTs favour this over naming programs with a stronger evidence base. This is because SLTs identify the need to support both a person with PPA and their CPs, who are equally distressed about conversation breakdown. We presently lack evidence to guide effective communication-based interventions in PPA. In response to this gap in the evidence base, the authors undertook a research study to develop and pilot a communication skills training program for people with PPA and their CPs. The BCA program for post-stroke aphasia was initially adapted to meet the needs of people with PPA using data collected from a UK-wide survey of speech and language therapy practice \[[@CR16]\] and a systematic review of the research literature on functional communication focused interventions for people with PPA and their families \[[@CR24]\]. It was further refined with SLTs who participated in a process using a nominal group consensus technique \[[@CR25]\] to agree with the intervention objectives and with people with PPA and their families who took part in a series of focus groups. A BCPPA steering group (of people with PPA, their family members and expert professionals) was established at the start of the work to provide advice and feedback on all aspects of study management, including the co-production of materials for the program and support for future dissemination of results. In terms of the MRC guidance on development and evaluation of complex interventions \[[@CR26]\], intervention refinement constituted phase I work to fully define BCPPA. This paper summarises the phase II randomised controlled pilot study protocol for the BCPPA program. Our UK-wide survey of SLTs \[[@CR16]\] shows that there is no standard speech and language treatment for people with PPA, thus it is not possible to have a usual care group for the study. Instead, a no speech and language therapy treatment control group has been used. The protocol has followed the CONSORT (Consolidated Standards of Reporting Trials) guidelines and the SPIRIT (Standard Protocol Items: Recommendations for Interventional Trials) statement \[[@CR27]\] as well as the TIDieR (Template for Intervention Description and Replication) checklist and guide \[[@CR28]\].

Aim {#Sec2}
---

The primary aim of this study is to pilot the BCPPA program compared to a no speech and language therapy treatment control group over participating sites to establish for a main trial whether BCPPA can be delivered as intended in an NHS setting. Specifically, the aim of piloting the BCPPA program compared to a no speech and language therapy treatment control group is to establish:The acceptability of randomisationAn assessment of BCPPA treatment fidelity to determine necessary levels of SLT trainingThe most appropriate primary outcome measureSample size calculationPredicted patient recruitment and retention ratesRefined inclusion criteria

Methods {#Sec3}
=======

Design {#Sec4}
------

This is a single blind, randomised controlled pilot study with BCPPA treatment versus no speech and language therapy treatment. Participants will be involved for a total of 6 weeks: pre-intervention measures (week 1); intervention/control (weeks 2--5); and post-intervention measures (week 6). See Fig. [1](#Fig1){ref-type="fig"} for participant flow chart through study.Fig. 1BCPPA participant flowchart through study

Setting {#Sec5}
-------

The seven participating NHS sites are located in England. Local collaborators (SLTs) at these sites will recruit participants, obtain consent, complete pre-intervention measures and deliver the BCPPA intervention across outpatient and community settings over a 20-month period.

Population {#Sec6}
----------

The study includes adults (\> 18 years) with a diagnosis or potential diagnosis of PPA (in view of the difficult and often protracted diagnostic process). See Table [1](#Tab1){ref-type="table"} for inclusion and exclusion criteria.Table 1Inclusion and exclusion criteria for potential participantsInclusion criteriaLocal collaborators at participating NHS sites will judge potential participants against the following criteria:\
(a) Have a diagnosis or possible diagnosis of PPA\
(b) Have some ability to communicate and understand communication in order to participate in the BCPPA program;\
(c) Are able to see and hear well enough to participate in the BCPPA program\
(d) Are functionally able to engage in the BCPPA program (i.e. able to maintain some concentration and remain in a 60--90 min session, minimal challenging behaviour that would be unlikely to cause disruption)\
(e) English as their language of daily use;\
(f) Have a conversation partner (CP) who is able to and consents to participating in the project.Exclusion criteriaPeople will be excluded from participation in the pilot if they:\
(a) Have a history of brain lesions or major head trauma;\
(b) Have major physical illness or disability which could impact on participation;\
(c) Present with a major psychiatric diagnosis;\
(d) Present with prominent behavioural disturbance;\
(e) Present with prominent episodic memory, visual memory, or visuoperceptual impairments.Note: The researchers acknowledge that the inclusion criteria may result in significant heterogeneity across participants---please refer to discussion of limitations

Identification and recruitment of participants {#Sec7}
----------------------------------------------

Local collaborators will be asked to identify people referred to their service who are suitable for the pilot using the inclusion and exclusion criteria (Table [1](#Tab1){ref-type="table"}) and invite them to participate. Local collaborators will complete a log to record the number of people with a diagnosis of PPA who do not meet the inclusion criteria, they will also record the number of people who are eligible but who have declined to participate in the study and their reasons why if provided. People who meet the inclusion criteria will not be under any obligation to take part in this research and this will be made clear from the outset. Potential participants will be provided with a participant information sheet (see Additional file [1](#MOESM1){ref-type="media"}) before informed consent is obtained at least 48 h later (see Fig. [2](#Fig2){ref-type="fig"} for consent flowchart).Fig. 2Consent flowchart

All participants in the study will be in the mild to moderate stages of PPA and therefore would generally be expected to be competent to give informed consent to participate, provided that appropriate care is taken to explain the research and sufficient time is allowed for them to reach a decision. Due to the brief nature of the participants' involvement in the study (5 weeks) it is not anticipated that decision-making capacity will change over this time; however, this will be monitored by the local collaborator who obtains consent following the Mental Capacity Act (MCA) \[[@CR29]\], Royal College of Speech and Language Therapists (RCSLT) guidelines \[[@CR30]\] and Good Clinical Practice Standards \[[@CR31]\]. The local collaborators are specialist SLTs with considerable experience of supporting individuals with communication and cognitive impairment and who complete annual mandatory training on the MCA \[[@CR29]\] and issues related to obtaining consent. If a local collaborator has any doubts regarding the capacity of a person with PPA to provide informed consent for this study, advice will be sought from the first author or an appropriate professional involved in their care, e.g. the GP, as is standard practice. Participant information sheets and consent forms (see the Additional files) have been designed to be dementia friendly \[[@CR32]\] and modified with advice from the study's steering group of people with PPA and their carers (Additional file [2](#MOESM2){ref-type="media"}).

Randomisation {#Sec8}
-------------

Randomisation will be conducted by the final author using a random number generator and stratified by site using blocks of four to balance across BCPPA treatment and no speech and language therapy treatment groups within each site. Block sizes will not be disclosed to local collaborators. Local collaborators will be informed of participant group allocation via email after pre-assessment has been completed.

Blinding {#Sec9}
--------

Post-intervention measures will be administered by a pair of junior researchers (student SLTs at UCL) with skills in the assessment of people with PPA but crucially blinded to group allocation. Participants and family members will be asked not to reveal their allocation during the post-assessment session. They will be reminded of this prior to their appointment, by letter and verbally, at the start of the session. Should the students become unblinded during the reassessment process, this will be documented and the reasons recorded.

Sample size justification {#Sec10}
-------------------------

As there are no data available to estimate a sample size, the recruitment of participants has been dealt with pragmatically. Based on discussion with clinicians at the primary research site, it is estimated that it will be possible to recruit 42 participants over an 18-month period at seven sites. This pilot will provide information on recruitment and retention and facilitate a sample size calculation for a future full trial. Recruitment will be reviewed at 2-month intervals during the study, and the recruitment strategy will be amended as necessary to achieve the target number.

Pre- and post-intervention measures {#Sec11}
-----------------------------------

Participants will complete pre-intervention language, communication and quality of life measures (see Table [2](#Tab2){ref-type="table"}) with the local collaborator in week 1 of the study. Completing assessment to gain an insight into areas of communication strength and difficulty prior to commencing intervention is routine procedure in speech and language therapy practice, and importantly, provides the opportunity for local collaborators to build rapport with participants before delivery of the intervention. All measures will be repeated after intervention at week 6 by a pair of junior researchers. In order to collect communication data, participants will be trained to independently use an iPad to video record conversation samples. A conversation topic list will be provided to support this process should they require it. Table [3](#Tab3){ref-type="table"} summarises the schedule of pre- and post-intervention measures.Table 2List of pre- and post-intervention measuresLanguage measures:\
1. Comprehensive Aphasia Test \[[@CR43]\]\
This language battery provides a profile of performance across all modalities of language production and comprehension.Communication measure:\
1. Video recordings of conversation samples\
This informal measure adapted from the Aphasia Conversation Measure \[[@CR21]\] identifies barriers and facilitators to conversation between the person with PPA and their CP and assesses changes in conversation after interventionQuality of life measures:\
1. Dementia Quality of Life Measure \[[@CR44]\]\
This questionnaire is designed to ask people with dementia to rate their quality of life across the three main domains of feelings, memory and everyday life.\
2. The Aphasia Impact Questionnaire \[[@CR45]\]\
A tool designed to measure the impact of living with aphasia across three domains of communication, participation and emotional well-being.\
3. Communication Confidence Rating Scale for Aphasia \[[@CR42]\]\
This is a questionnaire of communication confidence that uses a self-rating scale designed for people with aphasia.\
4. Perceived Stress Scale \[[@CR46]\] (completed by CP only)\
This is a self-report questionnaire for measuring the respondent's perception of stress.\
5. Zarit burden interview \[[@CR47]\] (completed by CP only)\
This is a caregiver self-report questionnaire for measuring personal and care strain.Table 3Schedule of pre- and post-intervention measuresConsent sessionPreintervention assessment (1 week)Treatment/control (4 weeks)Postintervention assessment (1 week)Final data collectionWeek01234567Conversation1a2i3i4a5a6i7i8iConversation video recording: a, assessor present but not in room; i, independent home recording

Description of the intervention {#Sec12}
-------------------------------

### BCPPA program {#Sec13}

BCPPA provides a protocol for SLTs to deliver a four-session communication training program for people with PPA and their CPs. Participant\'s pre-intervention video-recorded conversation samples will be used to provide clips for video feedback during intervention sessions. The manual is made available to local collaborators online. The intervention is described in detail in Additional file [1](#MOESM1){ref-type="media"}, using the TIDieR checklist \[[@CR28]\].

### No speech and language therapy treatment {#Sec14}

Those participants assigned to a no speech and language therapy treatment condition will receive usual healthcare provision (anticipated to include neurology, GP reviews, and allied health input such as physiotherapy). However, this will exclude speech and language therapy intervention for the duration of their participation in the study. The period of no speech and language therapy treatment will be 5 weeks -- 4 weeks when the treatment group will receive BCPPA and 1 week when all participants complete post-intervention measures. As there is no critical period for treatment delivery for people with PPA, after this brief period, the participants allocated to the no speech and language therapy treatment group will resume all aspects of local speech and language therapy provision without further interruption.

Training of local collaborators {#Sec15}
-------------------------------

Local collaborators will be trained to deliver the BCPPA program by the first author and will be provided with a training package including all required materials. Table [4](#Tab4){ref-type="table"} presents an overview of training content.Table 4Overview of training of local collaborators (SLTs)Training goals\
For local collaborators to be able to:\
• Identify potential participants who meet the study inclusion criteria\
• Consent participants to the study\
• Deliver the BCPPA program\
• Complete pre-intervention measures\
• Complete fidelity measures\
• Access the support and advice of the researcher (first author) throughout the studyPre-training work\
• Pre-reading materials from the Study Training Pack to support participant identification, completion of outcome measures and delivery of interventionDay 1. (4.5 h)\
• Overview study procedures.\
• Discuss inclusion/exclusion criteria with vignettes to problem solve\
• Discuss consent procedures and flow chart with accompanying case study.\
• Discuss purpose and process of video recording conversation samples as outcome measure and to support therapy\
• Practice video recording for conversation samples.\
• Observe sample video recordings and identify barriers and facilitators to conversation with a view to planning therapyDay 2. (4.5 h)\
• Discuss and practice completing remaining outcome measures\
• Discuss therapy sessions with practical role play tasks, practice completing session plans, and observe sample video recordings demonstrating delivery of intervention, including goal setting and having emotional conversations.\
• Discuss fidelity measures (video recordings, local collaborator adherence questionnaire, and participant feedback questionnaires)\
• Provide contact information for ongoing support

Assessment of treatment fidelity {#Sec16}
--------------------------------

In order to ensure treatment fidelity, each local collaborator's sessions with their first participant will be observed by the first author (via remote viewing of a video recording) and feedback will be provided over Skype or by telephone. After that, telephone and email support will occur as needed, to ensure knowledge and skills are maintained. In addition, to ensure adherence is maintained, local collaborators will be asked to audio record the intervention sessions with all participants. A random sample of 10% of recordings will be analysed using a treatment adherence checklist by two independent raters to permit an investigation of inter-rater reliability. A further 10% of this random sample will be analysed by a second rater, and any differences will be discussed and agreed. Local collaborators will also be asked to reflect on adherence by completing an adherence questionnaire and by documenting session length and tasks completed. These will be anonymously returned to the first author in pre-stamped addressed envelopes.

Assessment of acceptability of the intervention {#Sec17}
-----------------------------------------------

In order to ensure the treatment is acceptable to people with PPA, their CPs and local collaborators, each will be asked to provide feedback on the intervention. Accessible feedback forms will be given to participants with PPA and their CPs at every intervention session, to be completed and returned anonymously in pre-stamped addressed envelopes directly to the first author. Additionally, local collaborators will be asked to include feedback on acceptability as part of the adherence questionnaire, completed after every session.

Data management {#Sec18}
---------------

All personal information such as date of diagnosis, relevant medical and social history will remain confidential. Participants will be given a unique number which will be used on paperwork, assessment score sheets and in the names of all video files, and in all subsequent analysis documents and publications. Lists of participant names and their unique numbers (required to conduct the remote randomisation procedure) will be kept by a designated local collaborator in a locked cabinet at each NHS site. Each list will only contain the names of participants based at the relevant site.

Participants will consent to be video recorded in conversation for the purposes of outcome measurement and to provide clips for video feedback during intervention sessions. Participants' faces will be fully visible in these video recordings as people's expressions form a significant part of natural human communication, the focus of the intervention being piloted. Confidentiality can be guaranteed in the sharing of this footage at conferences and during teaching activities but not anonymity. Judicious selection of recordings will minimise this risk (e.g. footage where personal details are discussed will not be used, and names will be blanked out of the audio stream). Allied health professionals viewing this footage are bound by professional codes of ethics requiring them to maintain client confidentiality. Participants (and their CPs) will be asked whether they are willing to accept the possibility of being recognised, and can opt out of this use of their data whilst remaining part of the study. Only the research team members will have access to the entire video recorded data set. All transcripts of conversation data will be anonymised by the use of pseudonyms for all named people and places.

No data management committee will be established as it is felt that this short, small-scale pilot carries minimal risks. The study is compliant with General Data Protection Regulations. If information disclosed by any participant leads the first author to believe that a participant is at risk of harm or harming others, confidentiality will be broken to ensure safety.

Data analysis {#Sec19}
-------------

Analysis for this single blind, randomised controlled pilot study will involve both quantitative and qualitative methods. Language and quality of life assessment data will be entered into a database and analysed using the Statistical Package for the Social Sciences \[[@CR33]\]. All data will be explored to test for assumptions of normalcy. If assumptions are not met, appropriate non-parametric tests will be used. Repeated measures ANOVA will be used in the analysis with group (no speech and language therapy treatment, BCPPA treatment) as a between subject factor and time (pre-therapy and post-therapy) as a within subject factor. This information will be used to determine a suitable sensitive outcome measure and to perform a power calculation to determine sample size for a fully powered trial. Conversation data will be analysed following a procedure developed for the BCA intervention \[[@CR21]\] to identify change in the use of targeted strategies following intervention. This will involve counting barrier and facilitator behaviours in 5-min video samples selected from the pre- and post-intervention conversation samples. These counts will be analysed using Poisson Trend Test suitable for observations occurring in Poisson distribution. All pre-therapy conversations will be weighted the same as one another, as will all the post therapy conversations. Outcomes for different participants will be investigated using a Test for Homogeneity, where this is significant, and the effect for different dyads will be calculated using the Holm-Bonferroni procedure.

Descriptive statistics will be used to report recruitment, attendance, attrition, and reasons for dropout. A CONSORT (Consolidated Standards of Reporting Trials) and SPIRIT (Standard Protocol Items: Recommendations for Interventional Trials) \[[@CR27]\] flow chart will be used to present overall recruitment to and progression through the study (Fig. [1](#Fig1){ref-type="fig"}). Recruitment and retention rates will be used to support sample size calculations to inform a future full trial and plan the required number of sites to meet this target. Adverse events will also be recorded, and participant feedback forms examined to inform future recruitment procedures. Stroke-related aphasia trials in the UK NHS have reported recruitment rates of between 38 and 44% from potential participants at the research sites \[[@CR34]--[@CR36]\].

Analysis of fidelity and adherence data will inform future training needs. Although fidelity data is sparse for speech and language intervention trials, processes such as those deployed in our study have been shown to achieve an average of 80--100% fidelity \[[@CR37]--[@CR39]\]. Thus, we have selected 80% as the minimum target for fidelity. Acceptability of the intervention will be considered, based on analysis of the participant feedback forms and adherence data to inform further refinements of the intervention prior to a future full trial. Analysis of participant feedback and adherence data will use descriptive statistics. For open-ended questions or 'other' response categories, qualitative analysis will be used, specifically identifying themes and sub-themes using thematic analysis \[[@CR40]\].

Criteria for success {#Sec20}
--------------------

This study will be considered appropriate to proceed to a full trial if:▸Patients and local collaborators report generally positive views about acceptability of randomisation and of intervention as determined by evaluation of feedback forms;▸A suitable sensitive outcome measure is determined and sample size estimated;▸Local collaborator intervention-fidelity rate is at least 80%.

Assessment and management of risk {#Sec21}
---------------------------------

This is a low-risk study. It is possible that participants will not experience improvements as a result of the intervention. However, there is evidence to suggest that such interventions are effective for improving communication and well-being in adults with non-progressive aphasia and their carers \[[@CR14]\]. Importantly, there is no evidence to indicate that participants will experience any harmful effects. Most of the measures used in this study are frequently used in routine clinical practice with people with PPA. Additionally, the local collaborators are SLTs with skills to complete measures in a sensitive and supportive manner, minimising risk of distress. If participants do not feel emotionally or physically well enough to continue, then an assessment will be postponed. Video recording of conversations might also cause distress. To minimise the risk, we will ensure that as far as possible, the participants are familiarised with recording devices and understand why video recording is necessary. All procedures are set out within our participant information sheets (see Additional file [1](#MOESM1){ref-type="media"}) and consent forms, which were co-produced with the study steering group of people with PPA and their carers. Participants will be reminded that they can withdraw from the study at any time without giving a reason. Any adverse events will be recorded in the participant's medical record, and the study sponsor informed.

Discussion {#Sec22}
==========

To the best of our knowledge, this is the first randomised controlled UK pilot study of a conversation training intervention for people with PPA and their families. It will inform the feasibility of delivering a future full randomised controlled trial investigating the effectiveness of the BCPPA program in an NHS setting. There is little documented evidence of the impact of communication training for people with PPA and their CPs, yet there are reports of its widespread clinical use by SLTs across the UK \[[@CR15], [@CR16]\]. As in prior functional communication-focused PPA intervention studies \[[@CR41]\], BCPPA might improve subjective confidence in communication (using the Communication Confidence Rating Scale in Aphasia \[[@CR42]\] see Table [2](#Tab2){ref-type="table"} list of pre- and post- intervention measures) even if there is no clear impact on specific language measures, as well as potentially improving carer wellbeing. Thus, insights from this study will be of relevance to guide development of future research and in particular, trials of therapeutic interventions in PPA, as well as for clinical care for this population. The paucity of literature on functional communication-focused interventions for people with PPA makes the findings of interest to dementia researchers and SLTs, as well as people with PPA and their family members. The study will generate a unique dataset of language, conversation, and quality of life measures from people living with PPA and family members. It will lead to the identification of sensitive measures of the impact of functional communication-focused interventions for PPA. Additionally, the study will provide a rich source of information on acceptability of the BCPPA program to people with PPA and their CPs. Importantly, this study involves people with PPA and their families, and a group of expert SLTs, in the development of a manualised intervention program that meets their communication needs.

Study limitations include the inability to blind participants to group allocation, a common barrier in behavioural studies. Those allocated to the control group will not receive any intervention for 4 weeks as there is no comparable standard care intervention. Similarly, it is not possible to blind local collaborators delivering the intervention. For this reason, post-intervention assessment is not completed by the local collaborators but by pairs of junior researchers who will be blinded to group allocation. The inclusion criteria for this study may result in significant heterogeneity across participants in terms of language profile and communication difficulties, making it difficult to compare participants' skills pre and post intervention. Thus, a range of outcome measures are being piloted across language, communication, and quality of life to identify the most sensitive across all participants. BCPPA is designed to be tailored to an individual's needs, which may result in variation in the types of strategies identified and practiced. To counter this, the key components of BCPPA remain fixed, and measures of fidelity will demonstrate the consistency with which the intervention in delivered. A further potential limitation is ascertainment bias since access to speech and language therapy for PPA varies widely across the UK, and some of the likely barriers to access (socio-economic, cultural, linguistic, etc.) could also influence BCPPA outcomes. Despite these limitations, this study represents an important step toward a future full-scale RCT to determine the effectiveness of BCPPA for people with PPA and their family members.

The results of this study will be disseminated via presentations at national and international conferences and submitted for publication in peer reviewed scientific journals. In the medium term, the BCPPA program and training materials will be made available to SLTs via UCL's public e-learning platform, alongside BCA \[[@CR18]\]. With support from the study steering committee, results will be disseminated through professional and user group networks via publications and presentations, for example, at the PPA support group branch of the Rare Dementias Support Group based at UCL (<http://www.raredementiasupport.org/>).

Trial status {#Sec23}
------------

Trial registration number ISRCTN10148247. Recruitment commenced in November 2017 and is due to end in March 2019.

Additional files
================

 {#Sec24}

Additional file 1:Description of BCPPA program (TIDieR). (DOCX 24 kb) Additional file 2:Participant information sheet. (DOCX 2194 kb)
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